Rhythm Pharmaceuticals, Inc.
RYTM
Rangering i aksjer
#3066
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aksjekurs
$86.36
Sist synkronisert: 2026-10-16
Markedsverdi
$5.95B
Endring (1 dag)
-1.83%
Endring (1 år)
-21.69%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
EPS for Rhythm Pharmaceuticals, Inc. (RYTM)
EPS per June 2026 TTM: $-3.11
Ifølge de siste økonomiske rapportene og aksjekursen til Rhythm Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $-3.11. Ved slutten av 2023 hadde selskapet en EPS på $-3.20, en nedgang sammenlignet med EPS-en i 2022 som var $-3.51.
EPS-historikk for Rhythm Pharmaceuticals, Inc. fra 2012 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-3.11 | -28.34% |
| 2024 | $-4.34 | 35.63% |
| 2023 | $-3.20 | -8.83% |
| 2022 | $-3.51 | 156.20% |
| 2021 | $-1.37 | -53.72% |
| 2020 | $-2.96 | -20.00% |
| 2019 | $-3.70 | 54.81% |
| 2018 | $-2.39 | 89.68% |
| 2017 | $-1.26 | -18.71% |
| 2016 | $-1.55 | 42.20% |
| 2015 | $-1.09 | 70.31% |
| 2014 | $-0.64 | 48.84% |
| 2013 | $-0.43 | 19.44% |
| 2012 | $-0.36 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -656.91% |
US
|
|
| $-7.98 | 156.59% |
US
|
|
| $-5.29 | 70.10% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -991.96% |
NL
|
